Cancer Will No Longer Be a Financial Death Blow to Many Patients

Article

For oncologists, the impact of the Supreme Court's decision on the Affordable Care Act will likely mean that their patients will no longer be in danger of losing insurance or being denied insurance because of cancer.

James B. Yu, MD

For oncologists, the impact of the Supreme Court's decision on the Affordable Care Act will likely mean that their patients will no longer be in danger of losing insurance or being denied insurance because of cancer. The number of uninsured patients will be reduced dramatically.

I am hopeful that this will mean that cancer will no longer be a financial death blow to many patients, and that patients will not have to choose between paying the mortgage and paying for increasingly expensive chemotherapies and radiation treatments. As someone who researches comparative and cost effectiveness, I think any reexamination of cost-benefit for patients and emphasis on evidence-based practice is welcome.

More on the Supreme Court Decision

Derek Raghavan
Bruce Minsky
Nora Janjan
Michael Glod
James B. Yu
Lawrence Wagman
Recent Videos
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Two experts are featured in this series.
Related Content
As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?

As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?

Ariana Pelosci
November 28th 2025
Article

A recent study found that the number of practicing oncologists is declining as the US population ages and cancer diagnoses continue to increase.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

Tisa-Cel Maintains Efficacy at 5-Year Analysis in R/R LBCL

Tisa-Cel Maintains Efficacy at 5-Year Analysis in R/R LBCL

Ariana Pelosci
November 26th 2025
Article

ORR, DOR, PFS, and OS showed continued improvement for patients with relapsed/refractory LBCL receiving tisagenlecleucel.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

177Lu/SBRT Improves PFS in Oligorecurrent Hormone-Sensitive Prostate Cancer

177Lu/SBRT Improves PFS in Oligorecurrent Hormone-Sensitive Prostate Cancer

Ariana Pelosci
November 26th 2025
Article

In the 177Lu plus SBRT arm, the median PFS was 17.6 months vs 7.4 months in the SBRT alone arm for patients with oligorecurrent HSPC.

Investigators are currently assessing the safety and preliminary activity of AVZO-103 among patients with advanced solid tumors in a phase 1/2 trial.

Novel Bispecific ADC Earns FDA Fast Track Status in Urothelial Cancer

Russ Conroy
November 25th 2025
Article

Investigators are currently assessing the safety and preliminary activity of AVZO-103 among patients with advanced solid tumors in a phase 1/2 trial.